Abstract:

Introduction and assessment of international multi-center randomized control studies in gastrointestinal stromal tumor        SHEN Lin，LI Jian, QI Chang-song. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education of China), Department of GI Oncology，Peking University Cancer Hospital & Institute, Beijing 100142, China
Corresponding author: SHEN Lin, E-mail: linshenpku@163.com
Abstract    With the development of molecular mechanism study and new drugs, the treatment model of gastrointestinal stromal tumor has undergone revolutionary changes. A number of prospective randomized controlled clinical trials have evaluated the efficacy and safety of tyrosine kinase inhibitor in therapy for metastatic GIST, preoperative therapy, and postoperative adjuvant therapy, which provide important basis for the foundation of the best mode of GIST therapy.

Key words: gastrointestinal stromal tumor, tyrosine kinase inhibitor, randomized controlled trial

摘要：

随着分子机制研究的深入与大量新药的出现，胃肠间质瘤（gastrointestinal stromal tumor，GIST）治疗模式发生了革命性的变化，多项前瞻性随机对照临床研究探讨了酪氨酸激酶受体抑制剂（tyrosine kinase inhibitor，TKI）在转移性GIST的药物治疗、术前治疗、术后辅助治疗等不同领域的有效性与安全性，为GIST最佳治疗模式的建立提供了重要依据。

关键词: 胃肠间质瘤, 酪氨酸激酶抑制剂, 随机对照试验